Skip to Content

ACTOplus met Approval History

  • FDA approved: Yes (First approved August 29th, 2005)
  • Brand name: ACTOplus met
  • Generic name: pioglitazone and metformin
  • Dosage form: Tablets
  • Company: Takeda Pharmaceuticals
  • Treatment for: Diabetes, Type 2

ACTOplus met (pioglitazone and metformin) is a combination antihyperglycemic medication used in the management of type 2 diabetes.

Development History and FDA Approval Process for ACTOplus met

May 13, 2009Approval FDA Approves ACTOplus met XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
Aug 29, 2005Approval ACTOplus met Takeda Pharmaceuticals - Treatment for Type 2 Diabetes
Oct 29, 2004Takeda Submits New Drug Application for Combination Type 2 Diabetes Medication, Actoplus Met (pioglitazone HCl and metformin HCl)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.